ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 2229

Individual Entheseal Points Have Differential Frequency of Involvement and Impact on Patient Reported Outcomes in Patients with Active Psoriatic Arthritis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies
Abstract Number: 2230

Bimekizumab Treatment in Patients with Active PsA and Prior Inadequate Response to TNF Inhibitors: Sustained Efficacy and Safety Results from a Phase 3 Study and Its Open-Label Extension up to 1 Year
Abstract Number: 2231

Ixekizumab Significantly Improves Nail Disease and Adjacent Joint Tenderness and Swelling in Psoriatic Arthritis
Abstract Number: 2232

Guselkumab, an IL-23p19 Subunit–specific Monoclonal Antibody, Is Able to Bind CD64+ Myeloid Cells, Potently Neutralize IL-23 Produced from the Cells, and Mediate Internalization of IL-23
Abstract Number: 2233

Neutrophil Levels Associate with Early Improvement in Spinal Pain and Week 24 Multi-Domain Disease Control During Guselkumab Treatment in Active Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials
Abstract Number: 2234

Disagreement Between Patient and Physician Global Assessment over Time in Psoriatic Arthritis: Insight into Treatment Priorities
Abstract Number: 2235

Identifying Differentially Expressed Genes to Predict TNF-Alpha and IL-17A Inhibitor Response in Psoriatic Arthritis
Abstract Number: 2236

Guselkumab Provides Rapid Clinically Meaningful Improvements in Clinical and Patient Reported Outcomes and Sustained Disease Control of Psoriatic Arthritis
Abstract Number: 2237

Upadacitinib in Refractory Psoriatic Arthritis. Multicenter Study of 134 Patients in Clinical Practice
Abstract Number: 2238

Longitudinal Effect of Guselkumab on Biomarkers of Inflammation and Cardiovascular Risk in Bionaive Patients with Active Psoriatic Arthritis and High Systemic Inflammatory Burden: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study
Abstract Number: 2239

Achievement of Disease Control in PsA Patients Treated with Upadacitinib at Week 152: Post Hoc Analysis of the Long-term Extensions of Two Phase 3 Trials
Abstract Number: 2240

Persistence to Therapy Among Patients with Psoriatic Arthritis Treated with IL-17A or TNFα Inhibitors (IL-17Ai or TNFi)
Abstract Number: 2241

Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Abstract Number: 2242

Irrespective of the Number of Erosions at Baseline, Patients with Psoriatic Arthritis Treated with Ixekizumab Show Improved Clinical Outcomes
Abstract Number: 2243

Ultrasound Enthesitis Responsiveness versus Clinical Enthesitis Responsiveness: Week 52 Results of an Exploratory Analysis from a Phase 3b Study in Patients with Psoriatic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].